Moreover, the level of TGF-β in circulating EVs was used to identify patients that would benefit from immune checkpoint inhibitor therapy in non-small cell lung cancer, as patients with higher levels of EV-TGF-β were considered immunosuppressed and less sensitive to the therapy[130]. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.